Most Read Articles
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Teng Sung Shin, Joyce Lam Ching Mei, 03 Sep 2018
Bleeding disorders in children can be divided into acquired and congenital conditions, with the acquired being far more common than the congenital. Clinical bleeding manifestations can vary in severity. Identifying the root cause early is crucial to control and halt bleeding as well as to prevent the risk of future bleeding in a vulnerable age group. This can be achieved by a thorough and salient history, physical evaluation, and appropriate investigations. This review will describe the common causes of bleeding disorders in children and will suggest an approach to the workup and diagnosis of such disorders.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

IL-17A inhibitors superior to other immunomodulators in moderate-to-severe plaque psoriasis

07 Jul 2018
From the survey conducted, it is found that more than 80% of patients with psoriasis have experienced discrimination or humiliation across the world.

Interleukin 17A (IL-17A) inhibitors show better efficacy than ustekinumab in achieving clearance in adults with moderate-to-severe plaque psoriasis, a recent study has shown. Additionally, IL-17A inhibitors are generally more effective than etanercept, adalimumab and apremilast.

The network meta-analysis showed the following targeted immunomodulators in order of increasing relative risk (demonstrating greater likelihood) of achieving a 75-percent improvement on the Psoriasis Area and Severity Index (PASI) relative to placebo: apremilast (6.2), etanercept (9.6), adalimumab (13.0), ustekinumab (14.0), secukinumab (15.4), infliximab (16.2), brodalumab (17.3) and ixekizumab (17.9).

Infliximab, brodalumab and ixekizumab were shown to be statistically superior to apremilast, etanercept, adalimumab and ustekinumab. Furthermore, data from head-to-head studies showed similar results.

A previous network-meta-analysis showed that ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab and ustekinumab, as compared to placebo, were the best choices for achieving PASI 90 in patients with moderate-to-severe psoriasis based on moderate- to high-certainty evidence. [Cochrane Database Syst Rev 2017 Dec 22;12:CD01153

To assess the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis, the investigators conducted a systematic literature review of placebo-controlled and head-to-head randomized trials of eight targeted immunomodulators that evaluated clinical benefits or harm.

In addition, a network meta-analysis adjusted for placebo response was carried out to perform indirect comparisons between agents. A 75-percent improvement on the PASI was the primary outcome.

The present study was limited by mostly short-term evidence (covering 10–16 weeks) and by few direct comparisons, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Teng Sung Shin, Joyce Lam Ching Mei, 03 Sep 2018
Bleeding disorders in children can be divided into acquired and congenital conditions, with the acquired being far more common than the congenital. Clinical bleeding manifestations can vary in severity. Identifying the root cause early is crucial to control and halt bleeding as well as to prevent the risk of future bleeding in a vulnerable age group. This can be achieved by a thorough and salient history, physical evaluation, and appropriate investigations. This review will describe the common causes of bleeding disorders in children and will suggest an approach to the workup and diagnosis of such disorders.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.